Calliditas Therapeutics AB (publ) (CALT) Stock Analysis

What Calliditas Therapeutics AB (publ) does

Calliditas Therapeutics AB (publ) operates as a clinical-stage biopharmaceutical entity, committed to identifying, advancing, and commercializing therapeutic products. Its primary focus lies in developing treatments for rare (orphan) conditions, with a particular emphasis on disorders impacting the renal and hepatic systems. The company markets Nefecon, an orally administered formulation of budesonide, which functions as an immunosuppressive agent designed to address immunoglobulin A nephropathy, an autoimmune kidney disease. Its flagship investigational product is Setanaxib, a NOX inhibitor. Setanaxib is currently undergoing Phase 2b/3 clinical trials for primary biliary cholangitis. Furthermore, it is being evaluated in Phase 2 studies for various other indications, including squamous cell carcinoma of the head and neck, idiopathic pulmonary fibrosis, and type 1 diabetic kidney disease. Calliditas's pipeline also includes Budenofalk 3 mg oral capsules, which are under development for the treatment of autoimmune hepatitis. The company was established in 2004 and has its corporate headquarters located in Stockholm, Sweden.

Key metrics

ETFs linked to CALT

Broad-market and Healthcare sector ETFs an investor holding Calliditas Therapeutics AB (publ) is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CALT fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) trades under the ticker CALT on NASDAQ.

Which exchange is CALT listed on?

CALT is listed on NASDAQ.

What sector does Calliditas Therapeutics AB (publ) operate in?

Calliditas Therapeutics AB (publ) is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CALT in a portfolio?

PortView shows CALT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.